Question special
Lead Moderator

In this study, M. pneumonia, L. pneumophila and C. pneumonia were only detected in about 4% of patients which is lower than in the prior Marston et al study- though this study relied on PCR which is more specific. Interestingly, Postma et al from April 2015 of NEJM showed non inferiority in 90 day mortality in beta lactam mono therapy vs beta lactam plus macrolide or fluoroquinolone alone in hospitalized, non-ICU patients. Given low levels of isolation of "atypical bacteria" in the current study, does this question need for empiric atypical coverage for all patients with community acquired pneumonia admitted to the hospital?